Biogen, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.
Biogen, Inc. is a biotechnology company that specializes in treating neurological diseases. Through research, development, and distribution, this company helps people access treatments for disorders including Alzheimer’s, Multiple Sclerosis, and Spinal Muscular Atrophy.
(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)
Biogen creates positive Humankind Value in large part due to its contributions to Healthcare R&D ($77.3 B), Pharmaceuticals ($51.9 B), and Economic Value ($5.1 B). The last 150 years of medical innovation have contributed to modern life expectancies, which is why Healthcare is important to our measure of Humankind Value. Biogen’s positive value from Healthcare R&D and Pharmaceuticals is linked to an estimated 2,681,089.8 additional years of life for people worldwide. The company adds economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. The Humankind Value of this company could improve, however, with reductions in Greenhouse Gases (-$951.5 M) and Air Pollution (-$200.6 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities. This company has a positive Humankind Value even when analyzed alone, and the consideration of supply chain interactions pushes its Humankind Value higher.